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Oesophageal carcinoma is on the rise in all western
countries, currently with an incidence of 10/100, 000 in the
UK. As the numbers of gastric carcinoma cases fall worldwide,
the incidence of gastro-oesophageal junction tumours is
increasing. 1
Aetiology and classification
The main risk factors for development of carcinoma of the
oesophagus are listed in Table 1.  In particular, Barretts
oesophagus represents metaplastic change from the usual
stratified flat epithelium to an intestinal type columnar
epithelium. It is a pre-malignant condition although the rate of
conversion to malignancy is thought to be low, between
0.5-1.0% of cases. Patients with Barretts change require life long
endoscopic follow up with regular biopsies to assess for
dysplastic change. 2
Classification of Oesophageal Cancers
There are two main histological types of primary carcinoma
at this site, namely squamous cell carcinoma and
adenocarcinoma.  A number of rarer types have also been
identified (Table 2).  Twenty years ago, squamous cancers far
outnumbered any other histological type seen but now they
comprise 20-30% of all new cases, arising mainly in the upper
two thirds of the oesophagus.
In contrast adenocarcinoma in contrast now makes up
70 – 80 % of oesophageal  cancers, mainly in the lower third
and with background of Barretts metaplasia usually present .
Both arise as locally infiltrating tumours that spread
submucosally and radially through the muscular layers of the
oesophagus and beyond. Local and regional lymph node spread
is very common and is present in up to 80% of all cancers at
time of diagnosis. Routes of spread may be to nodes above as
well as below the diaphragm. Haematogenous spread occurs to
the liver, lungs and bones.
Clinical features
The survival rates of patients treated for oesophageal
carcinoma are poor, around 25 % at 3 years, mainly because of
the extent of disease at time of presentation with most patients
presenting late. 3  Between 30 and 40 % of all patients diagnosed
with oesophageal disease have localised malignancy and are fit
enough for surgery.
Increased awareness and regular endoscopic follow up of
Barretts oesophagus have begun to change the stage at which
diagnosis occurs although it is still too early to make any
confident statements about this. The symptoms leading up to
presentation vary as can be seen in Table 3.
Table 3: Symptoms
Painless dysphagia, initially to solids, progressing to
complete dysphagia to all fluids including saliva.
Weight loss
Pain either local or distal
Early satiety
Dyspepsia
Hoarseness from recurrent laryngeal nerve palsy
Table 1:  Risk factors
Alcohol
Tobacco
Diet - high in nitrosamines e.g. dried or smoked fish
Aflatoxin
Achalasia
Barretts oesophagus
Tylosis Palmaris
Plummer Vincent Syndrome
Caustic burns
Previous radiotherapy to the chest or neck
Male sex
Table 2: Less common histological types of oesophageal
cancers
Small cell carcinoma
Sarcoma
Melanoma
Mucoepidermoid carcinoma
Adenoid cystic carcinoma
Lymphoma
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Table 4: Palliative measures for local control 7
External beam radiotherapy
Brachytherapy
Endoscopic Photodynamic therapy
YAG laser endoscopic ablation
Expandable metal stent
Management of early disease
Surgical resection is the modality of choice for curative
treatment of early oesophageal carcinoma. The surgery is
complex, requiring a total oesophagectomy with gastric pull-up
and lymphadenectomy.
Once the diagnosis is obtained by endoscopic biopsy, work
up should include prone contrast-enhanced CT scan to assess
the degree of contact between the tumour and the aorta, and to
detect metastatic disease to the liver and lungs. Laparoscopy and
biopsy of affected nodes that may preclude resection is
undertaken.
Surgery alone will provide a 35% 3 year survival rate for early
disease. Most patients who relapse have distal metastases,
suggesting that micro-metastatic disease was present at the
outset.
 In the late 1990s, practice changed to include pre-operative
chemotherapy following the completion of the Medical Research
Council’s (MRC) OE – 02 randomised controlled trial. This paper
compared two cycles of chemotherapy pre-operatively with
surgery alone in 802 patients. Patients had to be deemed eligible
for radical surgery by the surgical team.
It showed that giving two cycles of chemotherapy
(Cisplatinum and 5 Fluorouracil) prior to surgery improves the
3-year survival by 9% increasing it to 44% (95% Confidence
interval [CI] 3-16%). Overall survival improved significantly in
the chemosurgery group (Hazard Ratio 0.79, CI 0.67-0.93,
p=0.004).
The rationale behind chemotherapy is to deal with micro-
metastatic disease as early as possible, giving the patient a better
chance at long term survival following successful surgery. Indeed,
complete resection rates were higher for those on chemo (60%
vs. 54%). The response rate to chemotherapy was high, with only
17% showing progressive growth.
Side effects of treatment are mild and post-operative
complications were similar in both groups. Furthermore
chemotherapy often results in symptomatic improvement within
days of the first cycle of chemotherapy.4
Although this study has its detractors and critics, it has been
embraced by surgical and oncological teams across the UK.
Current practice involves discussion of each new oesophageal
carcinoma patient in a multi-disciplinary meeting attended by
the radiologists, pathologists, surgeons, oncologists and clinical
nurse specialists.
All patients thought to be surgically resectable will be referred
to the oncologists, who assess the patient’s fitness for
chemotherapy, with most patients deemed fit.  Of course, close
co-operation between the teams is vital for the smooth co-
ordination of the various aspects of management.  Surgery is
scheduled for the third week after the second cycle of
chemotherapy has been delivered.
Combining chemotherapy and radiotherapy pre-operatively
is also gaining popularity following the publication of a number
of papers worldwide.  The morbidity of combining three toxic
treatments (chemotherapy, radiotherapy and surgery) is however
considerable5 and as a result, it has not yet been adopted as the
gold standard. Carefully selected fit patients may, however,
benefit from this combined modality treatment.
For those patients who are deemed inoperable for medical
reasons, combined chemoradiotherapy is an alternative to
surgery.  A landmark paper by Herskowicz in 1992 showed that
with combined chemoradiation using Cisplatin and 5 Flourouracil
concurrently with radiation to 50Gy, the 5-year survival rate could
be as high as 27% which is comparable to many series of surgical
survival.6   However, there are no randomised controlled studies
of radical chemoradiotherapy compared with surgery.
Palliative treatment
Sadly, for the many patients who relapse, or who have
metastatic disease at diagnosis there are no curative options.
Measures aimed at symptomatic control are effective and
varied (Table 4). These provide some improvement in swallowing
for a limited amount of time and sometimes the benefit may be
measured in months rather than weeks. The choice of palliation
depends on local availability as well as the patient’s level of fitness.
Chemotherapy may be offered to those who are still relatively
fit and well despite metastatic disease. This prolongs the median
survival of those with metastases to about 9 months, which is an
improvement of around 3 months. Early involvement of the
palliative care team is essential to ensure maximal benefit and
prolong survival
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